<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34030742</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2524-3489</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>3</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurological research and practice</Title>
          <ISOAbbreviation>Neurol Res Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>30</StartPage>
          <MedlinePgn>30</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">30</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s42466-021-00129-w</ELocationID>
        <Abstract>
          <AbstractText>Anti-glial nuclear antibody (AGNA) is an onconeuroal antibody targeting the nuclei of Bergmann glia in the cerebellum and Anti-SRY-related HMG-box 1 (SOX1). It is highly specific for small cell lung cancer (SCLC) and correlates to the appearance of paraneoplastic neurological syndromes such as Lambert-Eaton myasthenic syndrome (pLEMS) and paraneoplastic cerebellar degeneration (PCD) amongst others. Herein, we present a SCLC patient with rapidly progressive PCD, LEMS and axonal polyneuropathy associated with AGNA/SOX1-antibodies, successfully treated with plasma-exchange (PLEX).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Feldheim</LastName>
            <ForeName>Jonas</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-7297-4854</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Division of Clinical Neurooncology, University Hospital, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tumorbiology Laboratory, Department of Neurosurgery, University of Würzburg, Würzburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deuschl</LastName>
            <ForeName>Cornelius</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Glas</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Division of Clinical Neurooncology, University Hospital, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kleinschnitz</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Division of Clinical Neurooncology, University Hospital, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hagenacker</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany. tim.hagenacker@uk-essen.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany. tim.hagenacker@uk-essen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Res Pract</MedlineTA>
        <NlmUniqueID>101767802</NlmUniqueID>
        <ISSNLinking>2524-3489</ISSNLinking>
      </MedlineJournalInfo>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34030742</ArticleId>
        <ArticleId IdType="pmc">PMC8142469</ArticleId>
        <ArticleId IdType="doi">10.1186/s42466-021-00129-w</ArticleId>
        <ArticleId IdType="pii">10.1186/s42466-021-00129-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J. Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. Journal of Neuroimmunology. 2005;165(1-2):166–171. doi: 10.1016/j.jneuroim.2005.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2005.03.020</ArticleId>
            <ArticleId IdType="pmc">PMC2586939</ArticleId>
            <ArticleId IdType="pubmed">15949849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín-García E, Mannara F, Gutiérrez-Cuesta J, Sabater L, Dalmau J, Maldonado R, Graus F. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. Journal of Neuroimmunology. 2013;261(1-2):53–59. doi: 10.1016/j.jneuroim.2013.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.05.003</ArticleId>
            <ArticleId IdType="pubmed">23726906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Tan J, Sun H, et al.  Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. J Clin Neurol. 2020;16:530–546. doi: 10.3988/jcn.2020.16.4.530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2020.16.4.530</ArticleId>
            <ArticleId IdType="pmc">PMC7541980</ArticleId>
            <ArticleId IdType="pubmed">33029958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschernatsch M, Singh P, Gross O, Gerriets T, Kneifel N, Probst C, Malas S, Kaps M, Blaes F. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. Journal of Neuroimmunology. 2010;226(1-2):177–180. doi: 10.1016/j.jneuroim.2010.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2010.07.005</ArticleId>
            <ArticleId IdType="pubmed">20701982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: Practical guidelines and therapeutic challenges. Current Neuropharmacology. 2019;17(1):33–58. doi: 10.2174/1570159X16666180917105033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X16666180917105033</ArticleId>
            <ArticleId IdType="pmc">PMC6341499</ArticleId>
            <ArticleId IdType="pubmed">30221603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Medicine. 1998;4(11):1321–1324. doi: 10.1038/3315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/3315</ArticleId>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig, A., Muñiz-Castrillo, S., Desestret, V., Joubert, B., &amp; Honnorat, J. (2020). Pathophysiology of paraneoplastic and autoimmune encephalitis: Genes, infections, and checkpoint inhibitors. Therapeutic Advances in Neurological Disorders, 13, 1756286420932797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7318829</ArticleId>
            <ArticleId IdType="pubmed">32636932</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34030742</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2524-3489</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>3</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurological research and practice</Title>
          <ISOAbbreviation>Neurol Res Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>30</StartPage>
          <MedlinePgn>30</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">30</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s42466-021-00129-w</ELocationID>
        <Abstract>
          <AbstractText>Anti-glial nuclear antibody (AGNA) is an onconeuroal antibody targeting the nuclei of Bergmann glia in the cerebellum and Anti-SRY-related HMG-box 1 (SOX1). It is highly specific for small cell lung cancer (SCLC) and correlates to the appearance of paraneoplastic neurological syndromes such as Lambert-Eaton myasthenic syndrome (pLEMS) and paraneoplastic cerebellar degeneration (PCD) amongst others. Herein, we present a SCLC patient with rapidly progressive PCD, LEMS and axonal polyneuropathy associated with AGNA/SOX1-antibodies, successfully treated with plasma-exchange (PLEX).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Feldheim</LastName>
            <ForeName>Jonas</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-7297-4854</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Division of Clinical Neurooncology, University Hospital, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tumorbiology Laboratory, Department of Neurosurgery, University of Würzburg, Würzburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deuschl</LastName>
            <ForeName>Cornelius</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Glas</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Division of Clinical Neurooncology, University Hospital, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kleinschnitz</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Division of Clinical Neurooncology, University Hospital, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hagenacker</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany. tim.hagenacker@uk-essen.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany. tim.hagenacker@uk-essen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Res Pract</MedlineTA>
        <NlmUniqueID>101767802</NlmUniqueID>
        <ISSNLinking>2524-3489</ISSNLinking>
      </MedlineJournalInfo>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34030742</ArticleId>
        <ArticleId IdType="pmc">PMC8142469</ArticleId>
        <ArticleId IdType="doi">10.1186/s42466-021-00129-w</ArticleId>
        <ArticleId IdType="pii">10.1186/s42466-021-00129-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J. Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. Journal of Neuroimmunology. 2005;165(1-2):166–171. doi: 10.1016/j.jneuroim.2005.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2005.03.020</ArticleId>
            <ArticleId IdType="pmc">PMC2586939</ArticleId>
            <ArticleId IdType="pubmed">15949849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín-García E, Mannara F, Gutiérrez-Cuesta J, Sabater L, Dalmau J, Maldonado R, Graus F. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. Journal of Neuroimmunology. 2013;261(1-2):53–59. doi: 10.1016/j.jneuroim.2013.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.05.003</ArticleId>
            <ArticleId IdType="pubmed">23726906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Tan J, Sun H, et al.  Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. J Clin Neurol. 2020;16:530–546. doi: 10.3988/jcn.2020.16.4.530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2020.16.4.530</ArticleId>
            <ArticleId IdType="pmc">PMC7541980</ArticleId>
            <ArticleId IdType="pubmed">33029958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschernatsch M, Singh P, Gross O, Gerriets T, Kneifel N, Probst C, Malas S, Kaps M, Blaes F. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. Journal of Neuroimmunology. 2010;226(1-2):177–180. doi: 10.1016/j.jneuroim.2010.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2010.07.005</ArticleId>
            <ArticleId IdType="pubmed">20701982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: Practical guidelines and therapeutic challenges. Current Neuropharmacology. 2019;17(1):33–58. doi: 10.2174/1570159X16666180917105033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X16666180917105033</ArticleId>
            <ArticleId IdType="pmc">PMC6341499</ArticleId>
            <ArticleId IdType="pubmed">30221603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Medicine. 1998;4(11):1321–1324. doi: 10.1038/3315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/3315</ArticleId>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig, A., Muñiz-Castrillo, S., Desestret, V., Joubert, B., &amp; Honnorat, J. (2020). Pathophysiology of paraneoplastic and autoimmune encephalitis: Genes, infections, and checkpoint inhibitors. Therapeutic Advances in Neurological Disorders, 13, 1756286420932797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7318829</ArticleId>
            <ArticleId IdType="pubmed">32636932</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
